Skip to main content
. Author manuscript; available in PMC: 2019 Sep 3.
Published in final edited form as: Cell Rep. 2019 Apr 16;27(3):806–819.e5. doi: 10.1016/j.celrep.2019.03.066

Figure 1. MEK Inhibition Affects Murine Kras Mutant Tumor Growth and Murine T Cell Signaling.

Figure 1

(A) pERK expression in various Kras mutant lung cancer cell lines after trametinib treatment by western blot.

(B) Viability of lung tumor cell lines after selumetinib treatment. Samples were biological replicates.

(C) Survival of HKP1 lung-cancer-bearing mice after 3 weeks selumetinib treatment.

(D) pERK expression in CD4+ and CD8+ T cells from HKP1 tumor-bearing lungs after selumetinib or trametinib treatment by flow cytometry.

Samples were biological replicates. *p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001, Welch’s t test. NS, not significant. Error bars represent SD. The experiments were performed 2–3 times, and representative results are shown here.